弥漫性系统性硬化症患者停用或减量吗替麦考酚酯后进展性皮肤受累复发
结论提示MMF停药或减量后严重皮肤受累可复发,建议治疗维持超过2年。
要点
- 快速进展性弥漫性皮肤型系统性硬化症患者停用或减量MMF后,26.3%出现皮肤受累复发。
- 复发者平均mRSS增加35.9%,从7.8分升至10.6分,部分伴肺功能恶化。
- 重新启用MMF后皮肤和肺功能稳定或改善,提示治疗应维持超过2年。
核心结论
- 快速进展性弥漫性皮肤型系统性硬化症患者停用或减量MMF后,26.3%出现严重皮肤受累复发,需及时重新启用MMF。
- 研究结果提示MMF治疗应维持超过2年。
研究设计与样本
- 在平均2年后停用MMF或减量至≤1000 mg/天,随后5年系列评估mRSS和肺功能。
主要发现
- 复发者中2例同时出现呼吸症状恶化及肺功能检查肺容积下降。
- 重新启用MMF后,mRSS恢复至基线或稳定,肺功能改善或稳定,所有患者维持长期高剂量MMF治疗。
关键数值与推荐
- MMF减量至≤1000 mg/天或停药后,若mRSS增加>20%或出现限制性肺病,则重新启用MMF治疗。
临床怎么用
- 对快速进展性弥漫性皮肤型系统性硬化症患者,MMF治疗维持时间应超过2年,避免过早停药或减量。
- 停用或减量MMF后需密切监测mRSS和肺功能,一旦出现皮肤复发或肺功能恶化应及时重新启用MMF。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rapidly progressive diffuse cutaneous Systemic Sclerosis (rp-dcSSc) is associated with severe internal organ involvement and high mortality. Mycophenolate Mofetil (MMF) has been shown to halt the progression of rp-dcSSc cutaneous and pulmonary involvement in observational and randomized controlled trials, respectively. However, optimal MMF therapy duration has not been established. Here, we describe the clinical evolution of rp-dcSSc patients successfully treated with MMF following MMF therapy discontinuation or dose reduction. METHODS: Twenty-five patients with recent-onset (< 24 mo) rp-dcSSc received MMF as the only SSc disease-modifying therapy. Following MMF discontinuation or dose reduction to or below 1000 mg/day after an average of two years, the Modified Rodnan skin score (mRSS) and Pulmonary function tests (PFT) were serially evaluated for additional 5 years. MMF therapy was re-instituted if the mRSS increased by greater than 20% or if restrictive lung disease developed. RESULTS: From nineteen patients serially evaluated following MMF discontinuation or dose reduction, five patients (26.3%) developed recurrence of rapid skin involvement with an average of 35.9% increase in mRSS from 7.8 to 10.6 points requiring MMF re-institution. Two of these patients also presented worsening respiratory symptoms and reduction of lung volumes in PFTs. Following MMF resumption, mRSS returned to baseline or stabilized and PFTs improved or stabilized. All these patients were maintained on high dose long term MMF treatment. CONCLUSION: Recurrence of severe skin involvement occurred in 26.3% of patients with rp-dcSSc following MMF discontinuation or dose reduction, requiring prompt MMF therapy resumption. These findings confirm the therapeutic benefit of MMF in rp-dcSSc and suggest that MMF treatment should be maintained for longer than 2 years.
引用
- Mendoza FA, Lee-Ching C, Jimenez SA, et al. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis. Semin Arthritis Rheum. 2019. PMID: 31311679. doi:10.1016/j.semarthrit.2019.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。